La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Recce Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Les revenus et les bénéfices de Recce Pharmaceuticals devraient diminuer respectivement de 7.2% et de 56.3% par an, tandis que le BPA devrait croître de diminuer de 44.8% par an.

Informations clés

-56.3%

Taux de croissance des bénéfices

-44.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.8%
Taux de croissance des recettes	-7.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	17 Jul 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

OTCPK:RECE.F - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2026	5	-43	-43	-10	2
6/30/2025	7	-11	-11	-8	2
6/30/2024	5	-15	-14	-12	2
12/31/2023	7	-11	-9	-9	N/A
9/30/2023	6	-12	-11	-11	N/A
6/30/2023	4	-13	-13	-13	N/A
3/31/2023	4	-14	-14	-14	N/A
12/31/2022	3	-15	-15	-14	N/A
9/30/2022	3	-13	-12	-12	N/A
6/30/2022	3	-11	-9	-9	N/A
3/31/2022	2	-10	-8	-8	N/A
12/31/2021	1	-8	-7	-7	N/A
9/30/2021	1	-11	-8	-8	N/A
6/30/2021	2	-14	-8	-8	N/A
3/31/2021	1	-13	-8	-8	N/A
12/31/2020	1	-13	-8	-8	N/A
9/30/2020	1	-9	-6	-6	N/A
6/30/2020	1	-4	-4	-4	N/A
3/31/2020	1	-4	-3	-3	N/A
12/31/2019	1	-3	-3	-3	N/A
9/30/2019	1	-3	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	1	-2	-2	-2	N/A
12/31/2018	2	-2	-2	-2	N/A
9/30/2018	1	-2	-2	-2	N/A
6/30/2018	1	-2	-2	-2	N/A
3/31/2018	1	-2	-2	-2	N/A
12/31/2017	1	-3	-3	-2	N/A
9/30/2017	0	-3	N/A	-2	N/A
6/30/2017	0	-3	N/A	-2	N/A
3/31/2017	0	-3	N/A	-2	N/A
12/31/2016	0	-2	N/A	-2	N/A
9/30/2016	0	-4	N/A	-2	N/A
6/30/2016	0	-5	N/A	-2	N/A
3/31/2016	0	-5	N/A	-1	N/A
12/31/2015	0	-4	N/A	-1	N/A
9/30/2015	0	-2	N/A	0	N/A
6/30/2015	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: RECE.F devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: RECE.F devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: RECE.F devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Les revenus de RECE.F devraient diminuer au cours des 3 prochaines années ( -7.2% par an).

Croissance élevée des revenus: Les revenus de RECE.F devraient diminuer au cours des 3 prochaines années ( -7.2% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de RECE.F devrait être élevé dans 3 ans

Recce Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 08, 2023

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance